TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
64
PPD Phase 1
Austin, Texas, United States
Safety and tolerability
Adverse events, laboratory abnormalities, ECGs, and vital sign measurements.
Time frame: 11 days
Pharmacokinetics
Cmax, Tmax, AUC0-t, AUC0-24, AUCinf, CL, Vdss, t1/2, amount excreted in urine (Ae), fraction eliminated in urine (fe), and CLr.
Time frame: 96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.